Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
ConditionNASH - Nonalcoholic Steatohepatitis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorPerspectum
About this trial
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
Eligibility criteria
Qualifiers
Male and Female subjects aged between 18 and 75 years old
Ability to understand and sign a written informed consent forms
Patients scheduled to undergo a standard of care diagnostic liver biopsy as follows
Percutaneous biopsy with a 16 gauged needle passed into the right lobe
Disqualifiers
Prior histopathological diagnosis of NASH
Inability to undergo a liver biopsy
Prior or planned liver transplantation
Patient scheduled to undergo a laparoscopic or wedge liver biopsy or biopsy taken from the left lobe
Trial design
Treatments tested in this trial
- Liver Multi Scan
Treatment groups
225 Participants
are divided into 1 treatment groupLocations
7Arizona
Arizona Liver Health85224, Chandler United States
Illinois
RUSH University Medical Center60612, Chicago United States
Indiana
Indiana University Health46202, Indianapolis United States
New York
Icahn School of Medicine at Mount Sinai10029, New York United States
Sponsors and collaborators
Perspectum
Lead sponsor
Source ClinicalTrials.gov